Dr Konecny talks to ecancer at ESMO 2024 about his phase 1 study looking at novel agent TORL-1-23 targeting the oncofetal protein CLDN6.

A member of the claudin family of tight junction proteins, CLDN6 expression is limited to early stages of development, with aberrant expression in many cancers, including ovarian, endometrial, and testicular cancers.

TORL-1-23 was found to be well tolerated with preliminary antitumour activity in heavily-pretreated patients with CLDN6-expressing ovarian, endometrial, and testicular cancers.